Blog

Home  /  EUnetHTA Joint Action 3 (2016-2021)   /  PTJA10 – crizanlizumab indicated for the prevention of recurrent vast-occlusive crises in sickle cell disease patients aged 16 years and over – project plan now available

PTJA10 – crizanlizumab indicated for the prevention of recurrent vast-occlusive crises in sickle cell disease patients aged 16 years and over – project plan now available

The final project plan of the relative effectiveness assessment of ‘crizanlizumab indicated for the prevention of recurrent vast-occlusive crises in sickle cell disease patients aged 16 years and over’ is now available for access. The final assessment report will be published on 21st October, 2020.

Below is the documentation provided by the Joint Assessment Authoring Team:

PTJA10 – Final Project Plan